ASPU - Aspen Group, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.45
0.00 (0.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close8.45
Open8.34
Bid0.00 x 1000
Ask14.00 x 900
Day's Range7.95 - 8.46
52 Week Range3.58 - 8.67
Volume169,684
Avg. Volume116,174
Market Cap162.485M
Beta (5Y Monthly)0.90
PE Ratio (TTM)N/A
EPS (TTM)-0.36
Earnings DateDec 09, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
  • GlobeNewswire

    CORRECTION – Aspen Group Strengthens Balance Sheet to Begin 2020

    In a release issued under the same headline on Thursday, January 23rd by Aspen Group Inc. (ASPU), please note that in the second paragraph, the year for the beginning date should be 2020, not 2022. The Company has exchanged the secured $10 million term loan for $10 million of secured convertible notes at an interest rate of 7%. The convertible notes have a three year term and are convertible into Aspen Group common stock at a conversion price of $7.15 per share.

  • GlobeNewswire

    Aspen Group Strengthens Balance Sheet to Begin 2020

    NEW YORK, Jan. 23, 2020 -- January 23, 2020 – Aspen Group, Inc. (NASDAQ: ASPU) (“the Company” or “Aspen” or “AGI”), an education technology holding company, today announced the.

  • GlobeNewswire

    Aspen Group Announces Closing of Public Offering of Common Stock

    The number of shares sold by Aspen includes 315,000 shares of common stock pursuant to an option granted to the underwriters to cover overallotments that was exercised in full. Net proceeds from the offering to Aspen are approximately $16 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Aspen. Aspen intends to use the net proceeds from this offering to pay for expansion of its BSN pre-licensure program and for general corporate purposes and working capital.

  • Aspen, Carpenter Technology, Netflix, IBM and United Airlines highlighted as Zacks Bull and Bear of the Day
    Zacks

    Aspen, Carpenter Technology, Netflix, IBM and United Airlines highlighted as Zacks Bull and Bear of the Day

    Aspen, Carpenter Technology, Netflix, IBM and United Airlines highlighted as Zacks Bull and Bear of the Day

  • Bull Of The Day: Aspen Group (ASPU)
    Zacks

    Bull Of The Day: Aspen Group (ASPU)

    Bull Of The Day: Aspen Group (ASPU)

  • Uber Aims at Divesting Indian Food Delivery Unit to Zomato
    Zacks

    Uber Aims at Divesting Indian Food Delivery Unit to Zomato

    Uber's (UBER) sale of its food delivery business in India aims at loss reduction to enable the company earn profits in terms of EBITDA by 2021.

  • GlobeNewswire

    Aspen Group Announces Pricing of Public Offering of Common Stock

    In addition, Aspen has granted the underwriters of the offering a 30-day option to purchase up to 315,000 additional shares of its common stock to cover overallotments, if any. Net proceeds from the offering are expected to be approximately $13.9 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Aspen, but excluding any exercise of the underwriters’ option to purchase additional shares of common stock.

  • GlobeNewswire

    Aspen Group Announces Proposed Public Offering of Common Stock

    Aspen also expects to grant to the underwriters a 30-day option to purchase up to an additional 15% of shares of common stock offered in the public offering. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering. Aspen intends to use the net proceeds from this offering to pay for expansion of its BSN pre-licensure program and for general corporate purposes and working capital.

  • Analysts: The 5 Top Stocks You’ll Want to Own In 2020
    TipRanks

    Analysts: The 5 Top Stocks You’ll Want to Own In 2020

    We are still in the earliest days of the new decade, one sure to bring with it a plethora of changes. Some we can already foresee happening, while others remain unknowable to us.One certainty which will forever remain, though, involves investors’ hard-earned cash. Namely, everybody will always want to know where the best opportunities for ample returns lay.So, how to find out, then? As is de rigueur in the investment fraternity, the new year comes along with recommendation lists. Joining the fray is California based investment firm, Roth Capital. The company is adept at unearthing untapped potential with its primary focus on small-caps.We decided to get the scoop on 5 companies the investment firm thinks stand to make headway in 2020. All choices, according to the analysts, have room for solid upside, and, additionally, all currently hold a Strong Buy consensus rating from the Street. Here’s the lowdown.PowerFleet Inc (PWFL)Let’s start with one of Roth’s choices in the technology sector. Formerly known as I.D. Systems, PowerFleet is a pioneer in the use of radio frequency identification (RFID) technology for industrial asset tracking and management. With its patented systems for managing high value assets, the company serves big industry names such as Ford and Avis, as well as the U.S. Postal Service.The company’s latest earnings report achieved record quarterly revenue of $16.9 million, representing a year-over-year increase of 26%. The quarter also saw the company sign a number of deals with major players such as Knight-Swift, The Scotts Miracle-Gro Company, B.A.H. Express and Jungheinrich.In October PowerFleet completed the acquisition of Israeli based Pointer Telocation, a leading provider of telematics and mobile IoT solutions, for approximately $140 million. Roth’s William Gibson views “the combination as transformational, positioning the company for additional and larger orders.”“Our 2020 estimate is in line with guidance, earnings of $7.6 million or $0.26 per share on revenue of $153 million. Cross-selling opportunities are well underway and should result in meaningful upside to guidance,” the analyst said.Gibson, therefore, reiterated a Buy rating on PWFL, and kept his price target of $10.30 intact. Should the objective play out, gains of 46% could be heading investors’ way over the next 12 months. (To watch Gibson’s track record, click here)2 other analysts are currently tracking the asset tracker, with both recommending the stock a Buy. PowerFleet’s Strong Buy consensus rating is accompanied by an average price target of $10.83 and represents possible upside of 54%. (See PowerFleet stock analysis on TipRanks)Forty Seven Inc (FTSV)Moving on to the healthcare sector, we encounter Forty Seven Inc. The biotech is engaged in finding novel and more compassionate ways to fight cancer. FTSV has been turning heads on the Street recently, as December saw a tripling of its share price.The reason? Last month, Forty Seven announced promising updated clinical data from its ongoing phase Ib trial evaluating Magrolimab in combination with Azacitidine for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).The combination of Magrolimab and Azacitidine proved to be highly active and well-tolerated in patients with MDS and AML. Magrolimab is a humanized monoclonal antibody targeting CD47, which is a “don’t eat me” signal to macrophages and is expressed on all cells.After such a mercurial run up, what might move the stock even further?Roth’s Anthony Butler thinks It could be “inferences of magrolimab’s utility in solid tumors.” The 4-star analyst further expounded, “While we do not know the data, an early Phase Ib trial of magrolimab plus cetuximab in colorectal cancer will be presented at the Gastrointestinal Cancers Symposium (ASCO-GI) January 23-25 in San Francisco and as well as magrolimab plus avelumab in ovarian cancer at ASCO-SITC Clinical Immuno-Oncology Symposium February 6-8 in Orlando. The trials could possibly provide an early read on the utility of magrolimab in solid tumors. Any positive data most likely will increase the value of the stock.”Butler confirmed his bullish take on Forty Seven by reiterating a Buy rating on the cancer fighter. The analyst’s price target is $55 and implies upside potential of 56%. (To watch Butler’s track record, click here)It looks like the rest of the Street unanimously agrees with the Roth analyst. A Strong Buy consensus rating is formed of solely Buy ratings – 9, in fact. 13% upside could be in the cards should the average price target of $41.75 be achieved over the coming 12 months. (See Forty Seven stock analysis on TipRanks)NV5 Holdings (NVEE)NV5 Holdings suffered badly in the bull market of 2019, losing almost 17% of its value over the year. A series of disappointing earnings reports hampered the stock’s growth potential. The infrastructure-focused engineering and consulting company has started the new decade well, though, and is so far up by over 10% year-to-date.NV5 have been busy on the acquisition front; In December, the company completed the purchase of Geospatial Holdings (QSI), the US's largest independent geospatial analytics firm for approximately $318 million. The acquisition was the company’s 7th in 2019 alone.Roth’s Jeff Martin thinks a turnaround is due and foresees the trend extending further into 2020. The 5-star analyst said, “We chose NVEE as the top pick for Business Services in anticipation of the improved margin profile of the business in 2020. We model a 420bp improvement in adjusted EBITDA margin (on net revenue) to 21.2%, aided by the 24% margin from the QSI acquisition. QSI also brings organic growth potential and continued strength in NVEE’s Energy group aid in the return to organic growth in 2020.”Martin, accordingly, reiterated a Buy rating on NV5, along with a price target of $91. This implies upside potential of a not inconsiderable 63.5%. (To watch Martin’s track record, click here)Overall, those keeping an eye on NVEE stock remain with the bulls. NV5’s 3 Buy ratings coalesce into a Strong Buy consensus rating and come accompanied with an average price target of $87.33. The figure indicates upside potential of over 60% upside. (See NV5 stock analysis on TipRanks)Aspen Group Inc (ASPU)Combining tech with education, Aspen group has two for-profit universities under its holdings umbrella, Aspen University and United States University. The company provides online degrees along with on-campus studies.ASPU’s innovative monthly payment plan allows students to pursue degrees without the burden of student loans, while the university’s option to pay in monthly increments provides the ability to pay for education in significantly lower amounts. Aspen has been posting impressive growth figures in its latest earnings report, exhibiting 49% year-over-year growth, while also reporting record revenue of $12.1 million.Roth’s Darren Aftahi anticipates “continued topline growth (~36% y/y NTM) to be driven by further expansion of ASPU’s two higher growth and profit segments, USU and Pre-Licensure (PL).” The 5-star analyst further added, “We expect variable enrollment costs to be kept stable as ASPU should continue to benefit from its industry differentiating EdTech enrollment CRM (and with it double-digit conversion rates), suggesting continued leverage in marketing costs y/y, while maintaining double-digit enrollment growth (with upside in 2H20 from the launch of 2 additional PL campuses). Shares remain attractive trading at <2.5x FY21 revenue on ~30% y/y growth and runway for incremental profitability in the NTM.”Unsurprisingly, then, Aftahi kept his Buy rating on ASPU, along with his price target of $11. The figure indicates potential upside of 40%. (To watch Aftahi’s track record, click here)When put together, Aspen’s 4 Buy recommendations from the Street add up to a Strong Buy consensus rating. An average price target of $10.75 indicates possible gains of 36%. (See Aspen stock analysis on TipRanks)CryoPort Inc (CYRX)With Roth’s final pick we head back to the tech sector. Cryoport provide logistic solutions for the life sciences industry. Specifically, the company deals in the global transportation of temperature-sensitive materials and serves biopharmaceutical, IVF and surrogacy and animal health organizations around the world.The company is growing rapidly and making its way towards profitability. In 3Q19 revenues were up by 81% year-over-year with reported record revenue of $9.6 million. The company is expected to start turning a profit in 2021.After CYRX’s share price rose by over 150% in 2019’s first eight months, the final months of the year saw it experience a pullback. Roth’s Richard Baldry, though, sees the retracement as an opportunity. The 5-star analyst picks Cryoport’s as his “top Software sector pick for 2020.” Baldry said, “As CYRX’s clinical trial customer base increases and commercial therapies supported expand, we expect rapid growth and record revenue and earnings results in 2020, at odds with the roughly 40% pullback in its shares from recent highs.”To this end, Baldry reiterated a Buy on Cryoport, alongside a price target of $30. Should the target be met, investors stand to take home an increase in the shape of 75%. (To watch Baldry’s track record, click here)CYRX’s fans on the Street are few, yet vocal. Of the remaining 2 analysts chiming in with an opinion on the logistics company, both consider Cryoport a Buy. Therefore, Cryoport receives Strong Buy status. With an average price target of $23.67, the upside potential comes in at 38%. (See Cryoport price targets and analyst ratings on TipRanks)

  • Baidu (BIDU) Catches Eye: Stock Jumps 9.4%
    Zacks

    Baidu (BIDU) Catches Eye: Stock Jumps 9.4%

    Baidu (BIDU) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

  • Will Aspen Continue to Surge Higher?
    Zacks

    Will Aspen Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Aspen.

  • Did Hedge Funds Drop The Ball On Aspen Group Inc. (ASPU) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Aspen Group Inc. (ASPU) ?

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • GlobeNewswire

    Aspen Group Determines Not to Proceed with Proposed Public Offering of Common Stock

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy common stock or any other securities of Aspen Group in any jurisdiction. Aspen Group, Inc. is an education technology holding company that leverages its infrastructure and expertise to allow its two universities, Aspen University and United States University, to deliver on the vision of making college affordable again.

  • US$11.00 - That's What Analysts Think Aspen Group, Inc. Is Worth After These Results
    Simply Wall St.

    US$11.00 - That's What Analysts Think Aspen Group, Inc. Is Worth After These Results

    It's been a good week for Aspen Group, Inc. (NASDAQ:ASPU) shareholders, because the company has just released its...

  • GlobeNewswire

    Aspen Group Reports Record Revenue of $12.1 Million in the Second Quarter Fiscal Year 2020, Accelerating to 49% Growth Year-over-Year

    Net Loss Improves to ($0.6) Million as All Three Business Units Deliver Profitability on a Net Income Basis Company EBITDA Positive (a non-GAAP financial measure), Delivering.

  • GlobeNewswire

    Aspen Group, Inc. Appoints Frank J. Cotroneo Chief Financial Officer; Leadership Team Poised For Next Phase of Growth

    Aspen Group, Inc. (ASPU), an education technology holding company, today announced that it has named Frank J. Cotroneo Chief Financial Officer. Mr. Cotroneo, who has been a Board member of Aspen Group since 2018 and served as Chair of its Audit Committee, will take his new role effective immediately. Mr. Cotroneo brings an extensive background with more than 30 years of executive and finance leadership.

  • Top Ranked Momentum Stocks to Buy for November 18th
    Zacks

    Top Ranked Momentum Stocks to Buy for November 18th

    Top Ranked Momentum Stocks to Buy for November 18th

  • GlobeNewswire

    Aspen Group, Inc. to Present at the 12th Annual LD Micro Main Event on December 11, 2019

    NEW YORK, Nov. 18, 2019 -- Aspen Group, Inc. (Nasdaq: ASPU), an education technology holding company, today announced that Michael Mathews, Chairman and Chief Executive.

  • 3 Stocks That Wall Street Thinks Could Rise 40% or More
    TipRanks

    3 Stocks That Wall Street Thinks Could Rise 40% or More

    After a period of uncertainty, confidence has returned to the market and sent stock prices soaring. This raises the question, have stocks soared too high?Not according to Goldman Sachs’ Silvia Ardagna. The economist believes that while the global economy might be slowing down, the US economy is stronger than most other regions and there is yet more fuel left in the tank to propel it forward.“The de-escalation of trade tensions between the U.S. and China has triggered the question whether investors have been too negative and there could be some positive surprises,” said Ardagna, adding, “The main returns in our view still come from having an overweight to U.S. equities.”There’s no one true strategy to guarantee making money in the investment markets, but finding a stock a with strong upside potential is a good beginning. Today, we’ve used TipRanks’ Stock Screener to find three Strong Buys with buy-side potential over 40%. They come from a range of sectors – education, biopharmaceuticals, technology – and only two are showing positive performance so far this year. But all have attracted serious attention from high-rated analysts, who have seen clear paths toward high profitability for each of them.Aspen Group (ASPU)Starting in the education-tech field, Aspen Group operates two private, for-profit universities, the United States University based in San Diego and the distance-learning Aspen University. Both are accredited colleges and offer a variety of undergrad and post-graduate courses and programs.Education is an in-demand field, and Aspen’s Q1 fiscal 2020 earnings reflect that demand. Student enrollment was up 46% year-over-year, with 1,929 new enrollments, and revenues were up 43% to $10.4 million – a record for the company. CEO Michael Matthews noted a key point in the earnings: “Fiscal 2020 is off to a strong start with record revenue and enrollments in our seasonally weakest summer quarter.”After difficult stock performance through the summer, ASPU shares took off at the end of August, and the stock is up 21.5% year-to-date.Northland analyst Michael Grondahl notes an important point that is easily overlooked: Both of Aspen’s universities offer degrees and accreditation programs in nursing, a field in high demand. In his initiation-of-coverage report, Grondahl says of ASPU generally, “We believe Aspen Group represents a compelling opportunity as a higher-education provider that makes obtaining a degree more affordable and cost-worthy for students. ASPU has seen consistent enrollment growth, with total enrollment at just under 10,000 students.” His $10 price target suggests an impressive 50% upside potential for the stock. (To watch Grondahl's track record, click here)Aspen sells for a bargain $6.66, a price that is especially attractive when the upside potential is taken into account. The average price target, $9.75, indicates room for 46% growth to the upside in this stock. The Strong Buy analyst consensus is based on 4 Buy ratings set in the last two months. (See Aspen stock analysis on TipRanks)Sarepta Therapeutics (SRPT)Based in Cambridge, Massachusetts, Sarepta is a mid-cap ($7 billion) biotech company focusing on treatments for genetic disorders. The company’s first approved product, Exondys 51, is a treatment for Duchenne muscular dystrophy, and is approved for patients with a confirmed mutation in the DMD gene. Sarepta has 16 additional projects in the pipeline, mostly targeting forms of muscular dystrophy, and is a collaborator on 9 others.Unfortunately, Sarepta received devastating news in August. The FDA rejected the company's NDA application for golodirsen (SRP-4053) for the treatment of boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. The CRL, which is the FDA's euphemism for a rejection, outlined two main concerns: Intravenous (IV) infusion ports at risk of infections, and preclinical models of golodirsen displaying renal toxicity, observed following administration of other antisense oligonucleotides. Disappointed investors expecting the company to announce FDA approval pounded the stock all the way to a 52-week low of $72.05 in late September.However, SRPT has shown head-turning signs of life recently. Over the past five weeks, Sarepta stock has rallied about 30%, and Guggenheim analyst Whitney Ijem sees much more upside potential.Ijem gives an upbeat description of the company’s current standing in a November 1 initiation report: “We like the company's strategic positioning in DMD given its base RNA platform and leading gene therapy. Despite recent controversy on both, we expect positive progress in the next 6-12mos that should drive shares higher. Beyond DMD, the company has built an impressive pipeline of gene therapies in other neuromuscular diseases… we think current levels provide a highly favorable entry point ahead of what we expect will be a productive 2020.” Ijem’s $183 price target suggests a most impressive 94% upside to SRPT. (To watch Ijem's track record, click here)Indeed, the company’s robust pipeline, with 9 products in clinical testing and one Exondys 51 in commercial trials, shows that SRPT’s expenditures are going to a good end. Investors are willing to be patient with a biotech that has a strong research program.All in all, Sarepta has 18 buy ratings in the last three months, against a single hold – a clear sign that analysts and investors both are impressed with the company’s potential. Shares sell for $94, and the average price target of $191 gives the stock an eye-opening 101% upside. (See Sarepta's price targets and analyst ratings on TipRanks).Zix Corporation (ZIXI)In Zix, we move into the technology sector. This small tech company has a market cap of just $395 million, but a secure niche in the email security sector, providing encryption, data loss prevention, and mobile applications. Zix boasts over 80,000 customers, and bases its business on the popular – and profitable – cloud-based SaaS model. At the turn of the year, Zix made a significant acquisition when it bought AppRiver, a provider of cloud-based cyber security and productivity services.In Q3, reported at the end of October, ZIXI met the Street’s expectations with a 13 cent EPS. This was a 44% year-over-year gain. In terms of revenues, ZIXI beat the estimates by 1.16%, posting $47.83 million for the quarter. This was an impressive 168% increase from the year-ago quarter’s revenue figures. As fits a company with a healthy earnings profile, ZIXI shares are up 24% year-to-date, matching the performance of the S&P 500 index.Daniel Ives, 4-star analyst from Wedbush, initiated coverage on the stock last week, writing of the company, “Zix is a leader in the email encryption and delivery market providing security solutions to over 80,000 customers mainly focused on compliance driven industries such as Financial Services, Healthcare and Government. Email encryption accounts for almost 90% of its total revenue and today’s BYOD world presents many new security threats and challenges as we believe the company has strong differentiation from its competition [...] We believe that the Street does not currently fully appreciate the full potential of the AppRiver acquisition to drive top-line growth as well as EBITDA margin expansion.”Ives suggests that if everything goes as planned, ZIXI will be a $10 stock in the next 12 months, implying about 40% return. (To watch Ives' track record, click here)All in all, at just $7.10, ZIXI shares are another bargain for return-minded investors. The stock’s $10.33 average price target implies an excellent upside of 44%, and while the analyst consensus of Strong Buy is based on just three ratings, all three were given in the past two weeks. Clearly, this is a stock that is starting to attract attention from Wall Street’s analysts. (Get TipRanks' free stock analysis report on ZIXI)

  • GlobeNewswire

    Aspen Group, Inc. Reports a Quarterly Record 2,217 Enrollments, a 42% Increase Year-Over-Year; Quarterly Bookings Increase 92% Year-Over-Year to $31.3 Million

    NEW YORK, Nov. 11, 2019 -- Aspen Group, Inc. (“AGI”) (Nasdaq: ASPU), an education technology holding company, today announced record new student enrollments of 2,217 for the.

  • Aspen Group, Inc.'s (NASDAQ:ASPU) Path To Profitability
    Simply Wall St.

    Aspen Group, Inc.'s (NASDAQ:ASPU) Path To Profitability

    Aspen Group, Inc.'s (NASDAQ:ASPU): Aspen Group, Inc. provides online higher education services in the United States...

  • GlobeNewswire

    Aspen University Announces Initial Accreditation Approval of its Doctor of Nursing Practice Degree by Commission on Collegiate Nursing Education (CCNE)

    Aspen Group, Inc. (ASPU), an education technology holding company, today announced that the Commission on Collegiate Nursing Education’s (CCNE) Board of Commissioners acted at its October meeting to grant initial accreditation to Aspen University’s Doctor of Nursing Practice (DNP) degree program for the maximum period of five years, extending through 2024. According to standard CCNE procedures, Aspen was required to operate the program for at least a year and to graduate its first cohort prior to granting this initial accreditation.

  • GlobeNewswire

    Aspen Group, Inc. Announces the Promotion of Anne McNamara, Ph.D., RN to Chief Nursing Officer for Aspen Group, Inc.

    Aspen Group, Inc. (“AGI”) (ASPU), an education technology holding company, today announced that it has promoted Anne McNamara, Ph.D., RN to Chief Nursing Officer of the Company. In her new role as Chief Nursing Officer at Aspen Group, Inc., Dr. McNamara will provide academic and strategic oversight for Aspen Group’s nursing programs at Aspen University and United States University.